Molecular Diagnosis

, Volume 9, Issue 4, pp 181–186 | Cite as

Issues Concerning the Laboratory Investigation of Inherited Thrombophilia

  • Armando Tripodi
Review Article


Inherited thrombophilia, defined as an increased familial tendency to develop thrombosis, may be due to congenital deficiencies or abnormalities of antithrombin, protein C or protein S; to the presence of a point mutation in the factor V gene (G1691A, factor V Leiden) leading to a poor anticoagulant response to activated protein C; or to the presence of a mutation in the prothrombin gene (G20210A) leading to increased plasma levels of prothrombin. The laboratory investigation of inherited thrombophilia should be limited to patients with a history of venous thromboembolism and, if positive, to their family members even though they are still asymptomatic. There is no indication for indiscriminate screening of the general population or screening of asymptomatic women before prescribing oral contraceptives. Testing should be based on the phenotype for antithrombin, protein C and protein S; on the phenotype and genotype (factor V Leiden mutation) for activated protein C resistance; and on the genotype (G20210A mutation) for hyperprothrombinemia. Phenotypic testing should be performed no sooner than three months after acute thrombotic events and at least 2 weeks after discontinuation of oral anticoagulant treatment.


Venous Thromboembolism Antithrombin Factor Versus Thrombophilia Primary Prophylaxis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The author wishes to thank Dr Ida Martinelli for helpful discussion during the preparation of the manuscript. No sources of funding were used to assist in the preparation of this review. The author has no conflicts of interest that are directly relevant to the content of this review.


  1. 1.
    Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: part 1. Thromb Haemost 1996; 76: 651–62PubMedGoogle Scholar
  2. 2.
    Lane DA, Bayston T, Olds RJ, et al., for the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Antithrombin mutation database: 2nd (1997) update. Thromb Haemost 1997; 77: 197–211.PubMedGoogle Scholar
  3. 3.
    Carrell RW, Huntington JA, Mushunje A, et al. The conformational basis of thrombosis. Thromb Haemost 2001; 86: 14–22PubMedGoogle Scholar
  4. 4.
    Gandrille S, Borgel D, Ireland H, et al., for the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Protein S deficiency: a database of mutations. Thromb Haemost 1997; 77: 1201–14.PubMedGoogle Scholar
  5. 5.
    Ireland H, Thompson E, Lane DA. Gene mutations in 21 unrelated cases of phenotypic heterozygous protein C deficiency and thrombosis. Protein C Study Group. Thromb Haemost 1996; 76: 867–73PubMedGoogle Scholar
  6. 6.
    Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993; 90: 1004–8PubMedCrossRefGoogle Scholar
  7. 7.
    Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64–7PubMedCrossRefGoogle Scholar
  8. 8.
    Kalafatis M, Haley PE, Lu D, et al. Proteolytic events that regulate factor V activity in whole plasma from normal and activated protein C (APC)-resistant individuals during clotting: an insight into the APC-resistance assay. Blood 1996; 87: 4695–707PubMedGoogle Scholar
  9. 9.
    Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517–22PubMedCrossRefGoogle Scholar
  10. 10.
    Poort SR, Rosendaal FR, Reitsma PH, et al. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698–703PubMedGoogle Scholar
  11. 11.
    Bauer KA. Management of thrombophilia. J Thromb Haemost 2003; 1: 1429–34PubMedCrossRefGoogle Scholar
  12. 12.
    Marlar RA, Neumann A. Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies. Semin Thromb Hemost 1990; 16: 299–309PubMedCrossRefGoogle Scholar
  13. 13.
    Manco-Johnson MJ, Knapp-Clevenger R. Activated protein C concentrate reverses purpura fulminans in severe genetic protein C deficiency. J Pediatr Hematol Oncol 2004; 26: 25–7PubMedCrossRefGoogle Scholar
  14. 14.
    Vandenbroucke JP, van der Meer FJ, Heimerhorst FM, et al. Factor V Leiden: should we screen oral contraceptive users and pregnant women? BMJ 1996; 313: 1127–30PubMedCrossRefGoogle Scholar
  15. 15.
    Ridker PM, Miletich JP, Stampfer MJ, et al. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995; 92: 2800–2PubMedCrossRefGoogle Scholar
  16. 16.
    Simioni P, Prandoni P, Lensing AW, et al. The risk of recurrent venous thromboembolism in patients with an Arg506→Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997; 336: 399–403PubMedCrossRefGoogle Scholar
  17. 17.
    Simioni P, Prandoni P, Lensing AW, et al. Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. Blood 2000; 96: 3329–33PubMedGoogle Scholar
  18. 18.
    Eichinger S, Pabinger I, Stumpflen A, et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost 1997; 77: 624–8PubMedGoogle Scholar
  19. 19.
    Lindmarker P, Schulman S, Sten-Linder M, et al. The risk of recurrent venous thromboenibolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation. Thromb Haemost 1999; 81: 684–9PubMedGoogle Scholar
  20. 20.
    Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism [published erratum appears in N Engl J Med 1999; 341: 298]. N Engl J Med 1999; 340: 901–7PubMedCrossRefGoogle Scholar
  21. 21.
    Eichinger S, Weltermann A, Mannhalter C, et al. The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism. Arch Intern Med 2002; 162: 2357–60PubMedCrossRefGoogle Scholar
  22. 22.
    Miles JS, Miletich JP, Goldhaber SZ, et al. G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism. J Am Coll Cardiol 2001; 37: 215–8PubMedCrossRefGoogle Scholar
  23. 23.
    Eichinger S, Minar E, Hirschl M, et al. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost 1999; 81: 14–7PubMedGoogle Scholar
  24. 24.
    Koeleman BP, Reitsma PH, Allaart CF, et al. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031–5PubMedGoogle Scholar
  25. 25.
    Zoller B, Berntsdotter A, Garcia de Frutos P, et al. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518–23PubMedGoogle Scholar
  26. 26.
    van Boven HH, Reitsma PH, Rosendaal FR, et al. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemost 1996; 75: 417–21PubMedGoogle Scholar
  27. 27.
    Ridker PM, Hennekens CH, Selhub J, et al. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997; 95: 1777–82PubMedCrossRefGoogle Scholar
  28. 28.
    Rosendaal FR, Koster T, Vandenbroucke JP, et al. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504–8PubMedGoogle Scholar
  29. 29.
    Preston FE, Kitchen S, Jennings I, et al. A UK National External Quality Assessment Scheme (UK NEQAS) for molecular genetic testing for the diagnosis of familial thrombophilia. Thromb Haemost 1999; 82: 1556–7PubMedGoogle Scholar
  30. 30.
    Tripodi A, Peyvandi F, Chantarangkul V, et al. Relatively poor performance of clinical laboratories for DNA analyses in the detection of two thrombophilic mutations: a cause for concern. Thromb Haemost 2002; 88: 690–1PubMedGoogle Scholar
  31. 31.
    Tripodi A, Chantarangkul V, Menegatti M, et al. Performance of clinical laboratories for DNA analyses to detect thrombophilia mutations. Clin Chem 2005; 51: 1310–1PubMedCrossRefGoogle Scholar
  32. 32.
    Henkens CM, Bom VJ, van der Meer J. Lowered APC-sensitivity ratio related to increased factor VIII-clotting activity. Thromb Haemost 1995; 74: 1198–9PubMedGoogle Scholar
  33. 33.
    Tripodi A, Chantarangkul V, Mannucci PM. Hyperprothrombinemia may result in acquired activated protein C resistance. Blood 2000; 96: 3295–6PubMedGoogle Scholar
  34. 34.
    Olivieri O, Friso S, Manzato F, et al. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol 1995; 91: 465–70PubMedCrossRefGoogle Scholar
  35. 35.
    Cumming AM, Tait RC, Fildes S, et al. Development of resistance to activated protein C during pregnancy. Br J Haematol 1995; 90: 725–7PubMedCrossRefGoogle Scholar
  36. 36.
    Ehrenforth S, Radtke KP, Scharrer I. Acquired activated protein C-resistance in patients with lupus anticoagulants. Thromb Haemost 1995; 74: 797–8PubMedGoogle Scholar
  37. 37.
    de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93: 1271–6PubMedGoogle Scholar
  38. 38.
    Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 1999; 130: 643–50PubMedGoogle Scholar
  39. 39.
    Jorquera JI, Montoro JM, Fernandez MA, et al. Modified test for activated protein C resistance. Lancet 1994; 344: 1162–3PubMedCrossRefGoogle Scholar
  40. 40.
    Tripodi A, Negri B, Bertina RM, et al. Screening for the FV:Q506 mutation: evaluation of thirteen plasma-based methods for their diagnostic efficacy in comparison with DNA analysis. Thromb Haemost 1997; 77: 436–9PubMedGoogle Scholar
  41. 41.
    Trossaert M, Conard J, Horellou MH, et al. Modified APC resistance assay for patients on oral anticoagulants [letter]. Lancet 1994; 344: 1709PubMedCrossRefGoogle Scholar
  42. 42.
    Mannucci PM. Genetic hypercoagulability: prevention suggests testing family members. Blood 2001; 98: 21–2PubMedCrossRefGoogle Scholar
  43. 43.
    Green D. Genetic hypercoagulability: screening should be an informed choice. Blood 2001; 98: 20PubMedCrossRefGoogle Scholar
  44. 44.
    Middeldorp S, Meinardi JR, Koopman MM, et al. A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann Intern Med 2001; 135: 322–7PubMedGoogle Scholar
  45. 45.
    Simioni P, Tormene D, Prandoni P, et al. Incidence of venous thromboembolism in asymptomatic family members who are carriers of factor V Leiden: a prospective cohort study. Blood 2002; 99: 1938–42PubMedCrossRefGoogle Scholar
  46. 46.
    Sanson BJ, Simioni P, Tormene D, et al. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study. Blood 1999; 94: 3702–6PubMedGoogle Scholar
  47. 47.
    Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia: report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost 1995; 73: 151–61PubMedGoogle Scholar
  48. 48.
    Van Hylckama Vlieg A, Komanasin N, Ariens RA, et al. Factor XIII Val34Leu polymorphism, factor XIII antigen levels and activity and the risk of deep venous thrombosis. Br J Haematol 2002; 119: 169–75PubMedCrossRefGoogle Scholar
  49. 49.
    Tripodi A. Levels of coagulation factors and venous thromboembolism. Haematologica 2003; 88: 705–11PubMedGoogle Scholar
  50. 50.
    Kluijtmans LA, van den Heuvel LP, Boers GH, et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 58: 35–41PubMedGoogle Scholar
  51. 51.
    Tosetto A, Missiaglia E, Frezzato M, et al. The VITA project: C677T mutation in the methylene-tetrahydrofolate reductase gene and risk of venous thromboembolism. Br J Haematol 1997; 97: 804–6PubMedCrossRefGoogle Scholar
  52. 52.
    Brown K, Luddington R, Baglin T. Effect of the MTHFRC677T variant on risk of venous thromboembolism: interaction with factor V Leiden and prothrombin (F2G20210A) mutations. Br J Haematol 1998; 103: 42–4PubMedCrossRefGoogle Scholar
  53. 53.
    Frederiksen J, Juul K, Grande P, et al. Methylenetetrahydrofolate reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospective and case-control studies from the Copenhagen City Heart Study. Blood 2004; 104: 3046–51PubMedCrossRefGoogle Scholar
  54. 54.
    Hellmann EA, Leslie ND, Moll S. Knowledge and educational needs of individuals with the factor V Leiden mutation. J Thromb Haemost 2003; 1: 2335-9PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine and DermatologyUniversity and IRCCS Maggiore HospitalMilanoItaly

Personalised recommendations